Healthcare shares are flat to higher in pre-market trade.
Mylan Inc. ( MYL ) says its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg.
This product is the generic version of Novartis' Myfortic Delayed-release Tablets. Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application containing a Paragraph IV patent certification for Mycophenolic Acid Delayed-release Tablets, 360 mg, and was awarded 180 days of marketing exclusivity for this strength. The company received final approval from the U.S. Food and Drug Administration.
And, clinical-stage pharmaceutical company Aerie Pharmaceuticals, Inc. ( AERI ) reported Thursday top-line results from the recently completed Phase 1 pharmacokinetics (PK) study of AR-13324 eye drops, administered to 18 healthy individuals over an 8-day period to assess systemic exposure to the drug.
The completion of the PK study is an important step in preparing for two planned Phase 3 registration studies of AR-13324, which are expected to commence by mid-2014.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.